Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide

Market Overview - U.S. stocks opened 2026 with modest gains, with the Dow Jones Industrial Average and S&P 500 rising, while the Nasdaq Composite lagged behind, reflecting cautious optimism after a strong 2025 for equities [1] - Trading volumes were light, indicating a rebound from late-December weakness [1] Sector Performance - Chipmakers, particularly Nvidia and Micron, led early gains due to ongoing enthusiasm around AI demand, although weakness in several megacap technology and consumer discretionary stocks limited broader market gains [2] Economic Outlook - Investors are focusing on upcoming economic data and Federal Reserve signals to assess the outlook for rates and growth in 2026, with strategists cautioning that early January market movements may not dictate future trends [3] Bullish Stocks - Nike, Inc. shares rose nearly 3% following insider buying, which is seen as a vote of confidence in the company's turnaround strategy, with CEO Elliott Hill purchasing approximately $1 million in shares [4] - Energy Fuels Inc. exceeded its production guidance, mining over 1.6 million pounds of uranium and projecting Q4 sales around 360,000 pounds, generating approximately $27 million in revenue [6] - A potential SpaceX IPO in 2026 could significantly impact the market, potentially leading to capital rotation from Tesla as investors buy SpaceX shares, while ultimately benefiting Elon Musk-linked companies [5] Bearish Stocks - U.S.-listed Chinese tech stocks, including Alibaba, JD.com, and PDD Holdings, declined due to thin holiday trading volumes and disappointing economic data from China, reflecting broader market weakness [7] - Ultragenyx Pharmaceutical and Mereo BioPharma shares fell to 52-week lows after a late-stage clinical trial for a bone disease therapy failed to meet its primary endpoint [8] - Corcept Therapeutics shares dropped sharply following an FDA refuse-to-file letter for its investigational drug relacorilant, which surprised investors and led to reassessment of the company's regulatory pathway [9]